We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mepolizumab reduced the risk for a first severe ...
Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the completion of its Phase IIa clinical study for 9MW1911, a self-developed ...
In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...
The greatest risk factors for first severe exacerbation were advanced age, chronic oxygen therapy usage, COPD diagnosis type, dispensing of 4 or more canisters of rescue medication, and having 2 or ...
Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...
telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...
High-intensity noninvasive positive pressure ventilation (NPPV) might have reduced need for endotracheal intubation for persistent hypercapnia during acute exacerbation of chronic obstructive ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
The main goals of chronic obstructive pulmonary disease (COPD) management include treatment of symptoms and prevention of exacerbations. Current guidelines recommend use of one or more long-acting ...
CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback